Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.41 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26298196 | 0.92 | NAE1 (0.41) | ADKADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL264409 | 0.84 | SLC29A1 (0.59) | SLC29A1 | |
| SCHEMBL29674600 | 0.84 | SLC29A1 (0.59) | SLC29A1 | |
| SCHEMBL26298301 | 0.84 | ADK (0.48) | ADKADORA3ADORA2ASLC29A1 | |
| SCHEMBL264408 | 0.84 | SLC29A1 (0.59) | SLC29A1 | |
| SCHEMBL14733367 | 0.84 | SLC29A1 (0.59) | SLC29A1 | |
| SCHEMBL12601712 | 0.84 | ADK (0.48) | ADKADORA3ADORA2ASLC29A1 | |
| SCHEMBL21539907 | 0.84 | SLC29A1 (0.59) | SLC29A1 | |
| SCHEMBL22984010 | 0.84 | SLC29A1 (0.59) | SLC29A1 | |
| SCHEMBL889732 | 0.84 | ADK (0.48) | ADKADORA3ADORA2ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADK 648/4885ADORA3 197/4885ADORA2A 111/4885 |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADK 676/4885ADORA3 218/4885ADORA2A 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.